Propanc Biopharma, Inc.

Latest News

May 26, 2022

Propanc Biopharma Presents 100 Years of Clinical Evidence for “Novel” Enzyme Therapeutic Approach to Treat Cancer

MELBOURNE, Australia--(BUSINESS WIRE)-- Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from…

View All Press Releases

May 18, 2022

Propanc Biopharma Undertaking PRP Manufacturing & Development for Human Use

May 11, 2022

Propanc Biopharma Offers a Novel Way to Stop Cancer

May 2, 2022

Propanc Biopharma Purchases Pharma Grade Raw Materials for PRP Manufacture in Preparation for Phase I First-In-Human Study
Latest Publication Trypsinogen and chymotrypsinogen: potent anti- tumor agents View All Publications
Pancreatic (pro)enzymes treatment suppresses BXPC-3 pancreatic Cancer Stem Cell subpopulation and impairs tumour engrafting
Antitumour efficacy of chymotrypsinogen and trypsinogen
In vitro treatment of carcinoma cell lines with pancreatic (pro)enzymes suppresses the EMT programme and promotes cell differentiation